In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025").
More info..

China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10
More info..

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type.
More info..

China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
More info..

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
More info..

China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital.
More info..

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..

On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..

In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development.
More info..

On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..

More info..

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets ("Desidustat Tablets" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..

More info..

More info..

More info..

More info..

More info..

More info..

More info..

Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..

More info..

More info..

On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..

Gelonghui released a Press Release on "China Medical System Holdings Limited's innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets ('the Product') has obtained positive results for its Phase III clinical trial in China."
More info..

Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group"). CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average.
More info..

More info..

China Medical System Holdings Limited (0867.HK) ("CMS" or the "Company") has been active in the market this year.
More info..

As the earning season approaches, once again listed pharmaceutical companies are attracting the attention of the public. Recently, China Medical System Holdings Limited ("CMS" or the "Company") has released its annual results, with both revenue and profit higher than market expectations.
More info..